Radiofrequency ablation using the second-generation temperature-controlled diamond tip system in paroxysmal and persistent atrial fibrillation: results from FASTR-AF
- 18 May 2022
- journal article
- research article
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 66 (2) , 343-351
Abstract
Background Catheter ablation (CA) technology development reflects the need to improve the effectiveness of atrial fibrillation (AF) treatment. Recently, the DiamondTemp Ablation (DTA) RF generator software was updated with a more responsive power ramp. Methods DIAMOND FASTR-AF was a prospective, single-arm, multicenter trial. This study sought to characterize the performance of the updated DTA system for the treatment of patients with drug-refractory paroxysmal and persistent AF (PAF and PsAF). The primary effectiveness endpoint was freedom from atrial arrhythmia recurrence following a 90-day blanking period through 12 months, and the primary safety endpoint was a composite of serious adverse events. Results In total, 60 subjects (34 PAF and 26 PsAF) underwent CA at three centers. Patients were 71.7% male, (age 63.9 ± 10.2 years, with an AF diagnosis duration 3.1 ± 3.9 years and left atrial size 4.4 ± 0.8 cm). Pulmonary vein isolation-only ablation strategy was performed in 34 (56.7%) subjects. The procedural characteristics show a procedure time 90.8 ± 31.6 min, total RF time 14.7 ± 7.7 min, ablation duration 10.7 ± 3.6 s, and fluid infusion 284.7 ± 111.5 ml. The serious adverse event rate was 8.3% (5/60), 3 pulmonary edema and 2 extended hospitalizations. Freedom from atrial arrhythmia recurrence was achieved in 67.6% of subjects by 12 months. Conclusions The updated DTA system demonstrated long-term safety and effectiveness through 12 months of post-ablation follow-up for patients with atrial fibrillation. Additionally, procedures were demonstrated to be highly efficient with short procedure times and low levels of fluid infusion. Trial registration Sponsored by Medtronic, Inc.; FASTR-AF ClinicalTrials.gov; NCT03626649.Keywords
Funding Information
- EPIX Therapeutics
This publication has 21 references indexed in Scilit:
- 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillationEP Europace, 2017
- Safety and efficiency of porous-tip contact-force catheter for drug-refractory symptomatic paroxysmal atrial fibrillation ablation: results from the SMART SF trialEP Europace, 2017
- Temperature-Controlled Radiofrequency Ablation for Pulmonary Vein Isolation in Patients With Atrial FibrillationJACC, 2017
- Pulmonary Vein Re-Isolation as a Routine Strategy Regardless of SymptomsJACC: Clinical Electrophysiology, 2017
- EFFICAS II: optimization of catheter contact force improves outcome of pulmonary vein isolation for paroxysmal atrial fibrillationEP Europace, 2015
- Approaches to Catheter Ablation for Persistent Atrial FibrillationNew England Journal of Medicine, 2015
- Electrical Reconnection After Pulmonary Vein Isolation Is Contingent on Contact Force During Initial TreatmentCirculation: Arrhythmia and Electrophysiology, 2013
- Novel ablative approach for atrial fibrillation to decrease risk of esophageal injuryHeart Rhythm, 2008
- The effectiveness of a high output/short duration radiofrequency current application technique in segmental pulmonary vein isolation for atrial fibrillationEP Europace, 2006
- Spontaneous Initiation of Atrial Fibrillation by Ectopic Beats Originating in the Pulmonary VeinsNew England Journal of Medicine, 1998